REGENXBIO reports Q4 net income $294M on AbbVie deal; cash $849M into 2025

REGENXBIO Inc.

2021-FY EPS reported $2.91 revenue$470,347,000

Q4 2021 net income $294M ($6.87 basic EPS) vs net loss $46.2M in Q4 2020; revenue $398.7M (incl $370M AbbVie upfront).
Cash, equivalents & marketable securities $849.3M at Dec 31, 2021; runway into 2025.
Closed eye care collaboration with AbbVie: $370M upfront + up to $1.38B milestones; two pivotal trials (ATMOSPHERE, ASCENT) for wet AMD.
RGX-202: FDA cleared IND, granted Rare Pediatric Disease & Orphan Drug designations; Phase I/II AFFINITY DUCHENNE trial to start H1 2022.
RGX-314 suprachoroidal: Phase II AAVIATE (wet AMD) & ALTITUDE (DR) show reduced treatment burden; enrollment in higher-dose cohorts ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.